Pharmaceutical company Janssen-Cilag has announced the authorisation of Invega (paliperidone), a new treatment for schizophrenia.

In clinical trials, people treated with paliperidone experienced reductions in the symptoms of schizophrenia, as well as improvements in day-to-day personal and social functioning.

Paliperidone (prolonged-release tablets) is the first atypical antipsychotic treatment for schizophrenia to use OROS prolonged-release technology, which provides a steady release of medicine over a 24-hour period.